BreakSight, Inc.

BreakSight is a genomics startup advancing the way cancer drugs are characterized. Our platform analyzes how precision oncology treatments damage DNA at the sequence level. By capturing and sequencing these unique patterns of DNA damage, we help researchers discover new biomarkers—genetic clues that can predict whether a drug will be effective for specific patients. Currently, many cancer drugs are developed without fully understanding how they impact the genome. BreakSight fills this gap by providing detailed insights into how DNA damage occurs in response to different therapies. These insights can help drug developers make better decisions earlier in the process, potentially improving the success rate of new treatments. Why are these discoveries pivotal? Data generated by our platform can: 1. Reveal a drug’s unique effect on the cancer genome and sequence-specific mechanisms of genomic instability 2. Measure successful drug-target engagement at the genomic level 3. Pinpoint new DNA sequence biomarkers of drug efficacy that resides in the 98% of the genome left unexplored 4. Offer deeper DNA damage insights that might identify new therapeutic targets Our service platform: DDsite – - Performance of our assay to tag and retrieve DNA double-strand break sites across the genome from cells exposed to treatment(s) that induces DNA damage - Performance of next-generation sequencing on captured DNA break fragments DDinsight – - Analysis of sequence data through our stringent analysis pipeline to pinpoint reproducible sites of breakage across the genome - Uncovering DNA repeats and sequence motifs that are enriched across identified DNA break sites - Comparing sites across conditions Further customized analysis can be performed upon request.